Drug Profile
Ragweed mix vaccine - Woodmont Pharmaceuticals
Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Woodmont Pharmaceuticals
- Class Allergens; Antiallergics; Plant allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Allergic conjunctivitis; Seasonal allergic rhinitis
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for phase-I development in Allergic-conjunctivitis(In adolescents, In adults) in USA (Intralymphatic, Injection)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Seasonal-allergic-rhinitis(In adolescents, In adults) in USA (Intralymphatic, Injection)
- 21 Feb 2018 Woodmont Pharmaceuticals terminates a phase I trial as the sponsor withdrew IND from FDA in Allergic conjunctivitis and Seasonal allergic rhinitis (In adolescents, In adults) in USA (Intralymphatic) (NCT03038971)